Tags

Type your tag names separated by a space and hit enter

[E26 transformation-specific variant 4 promotes sorafenib and cisplatin resistance in hepatocellular carcinoma cells in vitro].
Nan Fang Yi Ke Da Xue Xue Bao 2019; 39(8):875-882NF

Abstract

OBJECTIVE

To investigate the role of E26 transformation-specific variant 4 (ETV4) in sorafenib and cisplatin resistance in hepatocellular carcinoma (HCC).

METHODS

HCC cell lines SMMC-7721 and HCC-LM3 were transfected with an ETV4- overexpressing plasmid or small interfering RNAs (siRNAs) targeting ETV4. The cells with ETV4 overexpression or ETV4 interference were treated with DMSO, sorafenib (5 μmol/L) or cisplatin (5 μmol/L) for 48 h, and the total protein and total RNA were collected. Western blotting, flow cytometry, EdU proliferation assay were used to analyze the apoptosis and proliferation of the cells. We also obtained clinical specimens of HCC tissues and paired adjacent tissues from 11 patients for detecting ETV4 mRNA expression levels using real-time fluorescence quantitative PCR (q-PCR). The effect of ETV4 interference on the mRNA expression levels of immediate early response gene 3 (IER3) was examined in HCC cells that were treated with DMSO, sorafenib or cisplatin for 48 h.

RESULTS

The expression of ETV4 mRNA was significantly higher in HCC tissues than in the paired adjacent tissues. Overexpression of ETV4 in the HCC cell lines obviously inhibited cell apoptosis induced by sorafenib or cisplatin. Conversely, ETV4 interference significantly enhanced the apoptosis and inhibited the proliferation of the HCC cells following treatments with sorafenib or cisplatin. In addition, ETV4 regulated the mRNA expression levels of IER3 in the cells treatmed with sorafenib and cisplatin.

CONCLUSIONS

ETV4 promotes resistance of HCC cells to sorafenib or cisplatin in vitro.

Authors+Show Affiliations

Department of Radiotherapy, Nanfang Hospita, Department of Oncology, Southern Medical University, Guangzhou 510515, China.Department of Radiotherapy, Department of Oncology, College of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China.Department of Radiotherapy, Nanfang Hospita, Department of Oncology, Southern Medical University, Guangzhou 510515, China.

Pub Type(s)

Journal Article

Language

chi

PubMed ID

31511205

Citation

Xiaohui, Chen, et al. "[E26 Transformation-specific Variant 4 Promotes Sorafenib and Cisplatin Resistance in Hepatocellular Carcinoma Cells in Vitro]." Nan Fang Yi Ke Da Xue Xue Bao = Journal of Southern Medical University, vol. 39, no. 8, 2019, pp. 875-882.
Xiaohui C, Xin LI, Dehua WU. [E26 transformation-specific variant 4 promotes sorafenib and cisplatin resistance in hepatocellular carcinoma cells in vitro]. Nan Fang Yi Ke Da Xue Xue Bao. 2019;39(8):875-882.
Xiaohui, C., Xin, L. I., & Dehua, W. U. (2019). [E26 transformation-specific variant 4 promotes sorafenib and cisplatin resistance in hepatocellular carcinoma cells in vitro]. Nan Fang Yi Ke Da Xue Xue Bao = Journal of Southern Medical University, 39(8), pp. 875-882. doi:10.12122/j.issn.1673-4254.2019.08.01.
Xiaohui C, Xin LI, Dehua WU. [E26 Transformation-specific Variant 4 Promotes Sorafenib and Cisplatin Resistance in Hepatocellular Carcinoma Cells in Vitro]. Nan Fang Yi Ke Da Xue Xue Bao. 2019 Aug 30;39(8):875-882. PubMed PMID: 31511205.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [E26 transformation-specific variant 4 promotes sorafenib and cisplatin resistance in hepatocellular carcinoma cells in vitro]. AU - Xiaohui,Chen, AU - Xin,L I, AU - Dehua,W U, PY - 2019/9/13/entrez PY - 2019/9/13/pubmed PY - 2019/9/13/medline KW - E26 transformation-specific variant 4 KW - apoptosis KW - drug resistance KW - hepatocellular carcinoma KW - proliferation SP - 875 EP - 882 JF - Nan fang yi ke da xue xue bao = Journal of Southern Medical University JO - Nan Fang Yi Ke Da Xue Xue Bao VL - 39 IS - 8 N2 - OBJECTIVE: To investigate the role of E26 transformation-specific variant 4 (ETV4) in sorafenib and cisplatin resistance in hepatocellular carcinoma (HCC). METHODS: HCC cell lines SMMC-7721 and HCC-LM3 were transfected with an ETV4- overexpressing plasmid or small interfering RNAs (siRNAs) targeting ETV4. The cells with ETV4 overexpression or ETV4 interference were treated with DMSO, sorafenib (5 μmol/L) or cisplatin (5 μmol/L) for 48 h, and the total protein and total RNA were collected. Western blotting, flow cytometry, EdU proliferation assay were used to analyze the apoptosis and proliferation of the cells. We also obtained clinical specimens of HCC tissues and paired adjacent tissues from 11 patients for detecting ETV4 mRNA expression levels using real-time fluorescence quantitative PCR (q-PCR). The effect of ETV4 interference on the mRNA expression levels of immediate early response gene 3 (IER3) was examined in HCC cells that were treated with DMSO, sorafenib or cisplatin for 48 h. RESULTS: The expression of ETV4 mRNA was significantly higher in HCC tissues than in the paired adjacent tissues. Overexpression of ETV4 in the HCC cell lines obviously inhibited cell apoptosis induced by sorafenib or cisplatin. Conversely, ETV4 interference significantly enhanced the apoptosis and inhibited the proliferation of the HCC cells following treatments with sorafenib or cisplatin. In addition, ETV4 regulated the mRNA expression levels of IER3 in the cells treatmed with sorafenib and cisplatin. CONCLUSIONS: ETV4 promotes resistance of HCC cells to sorafenib or cisplatin in vitro. SN - 1673-4254 UR - https://www.unboundmedicine.com/medline/citation/31511205/[E26_transformation-specific_variant_4_promotes_sorafenib_and_cisplatin_resistance_in_hepatocellular_carcinoma_cells_in_vitro] DB - PRIME DP - Unbound Medicine ER -